Laatste update :
18/04/2024
Antimycoticum   Caspofungin acetate  
Injecteerbaar geneesmiddel
Oogwater
Stabiliteit in oplossing Stabiliteit in mengsels Factoren die de stabiliteit beïnvloeden Verenigbaarheden Toedieningswijze Literatuur Pdf
   Molecuulstructuur  

Merknamen in verschillende landen   Merknamen in verschillende landen     

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Afundas Turkije
Cagin Peru
Cancidas Argentinië, Australië, België, Brazilië, Canada, Chili, Colombia, Denemarken, Duitsland, Ecuador, Finland, Frankrijk, Groot Britannië, Hongarije, Ierland, IJsland, Indië, Iran, Italië, Japan, Luxemburg, Maleisië, Mexico, Nieuw Zeeland, Noorwegen, Peru, Portugal, Roemenië, Saudi-Arabië, Turkije, USA, Verenigde Arabische Emiraten, Zweden, Zwitserland
Casfucid Chili, Ecuador, Peru
Casfung Ecuador, Indië
Caspodyan Chili
Caspofungin Australië, Denemarken, Duitsland, Finland, Griekenland, Groot Britannië, Hongarije, Ierland, Italië, Japan, Luxemburg, Nederland, Noorwegen, Oostenrijk, Polen, USA, Zwitserland
Caspofungina Brazilië, Chili, Ecuador, Spanje
Caspogin Indië
Caspopharm Peru
Casporan Indië
Caspovitae Chili, Peru
Driken Peru
Fentex Chili
Fhanigun Mexico
Fungidas Turkije
Monmix Mexico
Sanicid Chili
Suvepur Chili, Mexico
Ucaspo Ecuador
Literatuur   Injecteerbaar geneesmiddel   Literatuur : Caspofungin acetate  
Type Publicatie
1519 Fabrikant Caspofungine (Cancidas®) - Summary of Product Characteristics
Merck Sharp Dohme 2015
2017 Artikel Barker B, Feddema S, Rusho WJ, Dengg R.
Visual compatibility of vasopressin with other injectable drugs.
Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2233 Artikel Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 Artikel Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Artikel Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Artikel Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012 Artikel Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3140 Artikel Tsiouris M, Ulmer M, Yurcho J F, Hooper K L, Gui M.
Stability and Compatibility of Reconstituted Caspofungin in Select Elastomeric Infusion Device.
Int J Pharm Compound 2010 ; 14, 5 : 436-439.
3216 Artikel Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Artikel Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Artikel Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408 Artikel Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3728 Artikel Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766 Artikel Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Artikel Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3964 Artikel Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3976 Artikel Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055 Artikel Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4067 Artikel Pinder N, Pelzl L.H; Walther G, Backhaus J, Kurzai O, Hoppe-Ticky T.
Caspofungin infusion solutions (50 mg/mL): chemical stability and antifungal activity against Candida spp.
Pharmazie 2017 ;72:197-199
4145 Artikel Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Artikel Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4380 Fabrikant Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4528 Artikel Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4603 Artikel Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Fabrikant Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4655 Artikel Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33

  Mentions Légales